OR7-4: A phase 2, six-month dose-response study to investigate TransCon hGH, a long-acting hGH, in treatment naïve children with idiopathic growth hormone deficiency (IGHD)

Status of long-acting-growth hormone preparations — 2015

“…IGF-I levels increased in a dose-dependent manner and demonstrated a similar response for ACP-001 0.04 mg/kg/week compared to the corresponding dose of daily GH (0.04 mg/kg/week) [40]. In a six month phase 2 study of TransCon in 52 prepubertal children with idiopathic GHD the increase in IGF-I levels was comparable to daily GH injections [41]. The study showed good tolerability and safety [41].…”

“…In a six month phase 2 study of TransCon in 52 prepubertal children with idiopathic GHD the increase in IGF-I levels was comparable to daily GH injections [41]. The study showed good tolerability and safety [41].…”